Team:MIT/Project

From 2014.igem.org

(Difference between revisions)
Line 109: Line 109:
<tr>
<tr>
<td width="45%"  valign="top">  
<td width="45%"  valign="top">  
-
<p>Tell us more about your project.  Give us backgroundUse this as the abstract of your projectBe descriptive but concise (1-2 paragraphs) </p>
+
<p>
 +
Alzheimer's disease is a neurodegenerative disease that afflicts nearly
 +
30 million people worldwide.  It is characterized by the aggregation of
 +
beta-amyloid oligomers and plaques which cause neuron death and inhibit
 +
the proper functioning of surviving neurons. There is no definitive
 +
molecular detection or treatment mechanisms for the disease; this is
 +
what MIT iGEM 2014 seeks to address in our project, The Diagnosis and
 +
Treatment of Alzheimer's Disease.
 +
 
 +
We built two systems to detect Alzheimer's disease in the brain. The
 +
first is a detection system for beta-amyloid, in which extracellular
 +
oligomers bind to a transmembrane receptor and result in the release
 +
of a transcription factorFor this detection system, we employed two
 +
different beta-amyloid specific receptors: LilrB2, a protein receptor
 +
found naturally occuring in the human immune system; and a synthetic
 +
B-cell receptor we designed based on an antibody that recognizes
 +
beta-amyloid.
 +
 
 +
The second system detects the disease using a different biomarker: an
 +
intracellular microRNA profile, specific to neurons affected by
 +
Alzheimer'sCells express different miRNAs according to their cell
 +
type and disease state. It is known that several miRNAs are up- or down-
 +
regulated in “Alzheimer’s state” neurons compared to healthy ones. Using
 +
this knowledge, we have built 2 sensors: a "low" sensor to detect miRNAs
 +
that are down-regulated compared to healthy neurons, and a "high"
 +
sensor to detect miRNAs which are up-regulated. These sensors can then
 +
be combined to sense the specific combination of miRNAs that indicate a
 +
neuron in the Alzheimer's state.
 +
 
 +
Finally, we designed a treatment module that could be activated by one
 +
of the detection modules to actually treat Alzheimer's diseaseIn
 +
order to treat the disease, we aim to reduce the number of beta-amyloid
 +
oligomers and plaques in the brain. We do this by expressing a
 +
beta-amyloid-degrading enzyme – BACE2 – and down-regulating an
 +
endogenous enzyme that is crucial for beta-amyloid formation – BACE1.
 +
This module can be coupled to any of our diagnostic modules to form an
 +
integrated circuit to diagnose and treat Alzheimer's disease.</p>
<br>
<br>
<h3>References </h3>
<h3>References </h3>

Revision as of 00:29, 16 August 2014



MIT iGEM 2014

Our wiki is currently under construction, so please bear with us as we continue to update it over the coming weeks.


Click here to edit this page!

Home Team Official Team Profile Project Parts Modeling Notebook Safety Attributions
What is Alzheimers Diagnosis Treatment Delivery

Project Description

Content

Alzheimer's disease is a neurodegenerative disease that afflicts nearly 30 million people worldwide. It is characterized by the aggregation of beta-amyloid oligomers and plaques which cause neuron death and inhibit the proper functioning of surviving neurons. There is no definitive molecular detection or treatment mechanisms for the disease; this is what MIT iGEM 2014 seeks to address in our project, The Diagnosis and Treatment of Alzheimer's Disease. We built two systems to detect Alzheimer's disease in the brain. The first is a detection system for beta-amyloid, in which extracellular oligomers bind to a transmembrane receptor and result in the release of a transcription factor. For this detection system, we employed two different beta-amyloid specific receptors: LilrB2, a protein receptor found naturally occuring in the human immune system; and a synthetic B-cell receptor we designed based on an antibody that recognizes beta-amyloid. The second system detects the disease using a different biomarker: an intracellular microRNA profile, specific to neurons affected by Alzheimer's. Cells express different miRNAs according to their cell type and disease state. It is known that several miRNAs are up- or down- regulated in “Alzheimer’s state” neurons compared to healthy ones. Using this knowledge, we have built 2 sensors: a "low" sensor to detect miRNAs that are down-regulated compared to healthy neurons, and a "high" sensor to detect miRNAs which are up-regulated. These sensors can then be combined to sense the specific combination of miRNAs that indicate a neuron in the Alzheimer's state. Finally, we designed a treatment module that could be activated by one of the detection modules to actually treat Alzheimer's disease. In order to treat the disease, we aim to reduce the number of beta-amyloid oligomers and plaques in the brain. We do this by expressing a beta-amyloid-degrading enzyme – BACE2 – and down-regulating an endogenous enzyme that is crucial for beta-amyloid formation – BACE1. This module can be coupled to any of our diagnostic modules to form an integrated circuit to diagnose and treat Alzheimer's disease.


References

iGEM teams are encouraged to record references you use during the course of your research. They should be posted somewhere on your wiki so that judges and other visitors can see how you though about your project and what works inspired you.

You can use these subtopics to further explain your project

  1. Overall project summary
  2. Project Details
  3. Materials and Methods
  4. The Experiments
  5. Results
  6. Data analysis
  7. Conclusions

It's important for teams to describe all the creativity that goes into an iGEM project, along with all the great ideas your team will come up with over the course of your work.

It's also important to clearly describe your achievements so that judges will know what you tried to do and where you succeeded. Please write your project page such that what you achieved is easy to distinguish from what you attempted.